Pfizer has settled a patent infringement lawsuit with India-based Dr Reddy’s Laboratories, relating to the company’s Lipitor medication.

The case stems back to December 2009, when Pfizer launched proceedings against Dr Reddy’s in order to block generic versions of Lipitor patent expiry in 2016 and 2017.

Although financial terms have not been disclosed, the settlement is subject to review by the US Justice Department and Federal Trade Commission.

The agreement comes on the back of similar settlements reached between Pfizer and the likes of Teva Pharmaceuticals and Mylan, which have both sought to market their own generic versions of Pfizer’s blockbuster cholesterol-reducer.